Cancer Research Cancer Research Funding Available  EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 53, 120-126, January 1, 1993]
© 1993 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wikstrand, C. J.
Right arrow Articles by Bigner, D. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wikstrand, C. J.
Right arrow Articles by Bigner, D. D.

Lactotetraose Series Ganglioside 3',6'-isoLD1 in Tumors of Central Nervous and Other Systems in Vitro and in Vivo1

C. J. Wikstrand, D. C. Longee2, R. E. McLendon, G. N. Fuller, H. S. Friedman, P. Fredman, L. Svennerholm and D. D. Bigner3

Departments of Pathology [C. J. W., D. C. L., R. E. M., G. N. F., H. S. F., D. D. B.] and Pediatrics [H. S. F.], and Preuss Laboratory for Brain Tumor Research [H. S. F., D. D. B.], Duke University Medical Center, Durham, North Carolina 27710; and Department of Psychiatry and Neurochemistry, University of Göteborg, Göteborg, Sweden [P. F., L. S.]

Two monoclonal antibodies, DMAb-21 and DMAb-22, directed against the lactotetraose series ganglioside-associated epitope IV3NeuAc,III6-NeuAcLcOse4Cer (3',6'-isoLD1), were found to define the minimum binding epitope NeuAc(or NeuGc){alpha}2-3Galß1-3(NeuAc or NeuGc){alpha}2-6GlcNAc. The distribution of 3',6'-isoLD1 in cultured cell lines and derived xenografts of primary tumors of the human central nervous system and of embryonal or neuroectodermal tumor derivation was determined. Only 4 of 26 cell lines, 3 teratomas and 1 pancreatic adenocarcinoma, expressed detectable 3',6'-isoLD1 when cultured in vitro; none of 14 tested glioma lines, including 2 that expressed the monosialo-precursor IV3NeuAcLcOse4Cer in vitro, expressed detectable levels. Expression of 3',6'-isoLD1 was more frequent when neoplastic cells were grown in xenograft form in athymic mice; 4 of 10 glioma and 2 of 2 teratoma xenograft ganglioside extracts were positive for 3',6'-isoLD1. The absence of 3',6'-isoLD1 in cultured tumor cells of the central nervous system and its proportional increased presence in tumor cells of the same origin grown in vivo further supports previous studies suggesting that ganglioside expression may be modified by environmental forces. The expression of lacto series gangliosides both in vitro and in vivo by teratoma and pancreatic adenocarcinoma cells, as opposed to only in vivo expression by glioma cells, suggests that tissue-specific forces may also exist. Immunohistochemical localization of 3',6'-isoLD1 in frozen sections of primary central nervous system neoplasms including those of glial and nonglial origin was performed; 20 of 30 (67%) of glial tumors were positive. Among nonglial tumors, 21 of 34 (62%) of epithelial cancers were reactive with anti-3',6'-isoLD1 monoclonal antibodies; notably negative were carcinomas of the ovary and lung carcinomas of all subtypes. Lymphomas and infiltrative lymphocytes were uniformly negative. The restriction of 3',6'-isoLD1 expression within the human central nervous system to periods of fetalneonatal astroglial proliferation, to intense reactive astrocytosis, and to primary neoplasms, and the production of specific monoclonal antibodies to this epitope provide a specific complex for immunolocalization and, eventually, immunotherapy.

1 Supported by NIH Grants CA 11898, NS 20023, T32-NS 07304, CA 56115, and CA 44640; by the Swedish Medical Research Council (Project 03X-09909-01); and by the National Swedish Board for Technical Development (Project 84-4667P).

2 Present address: Division of Hematology/Oncology, Arkansas Children's Hospital, 800 Marshall Street, Little Rock, AR 72202-3591.

3 To whom requests for reprints should be addressed, at Box 3156, Department of Radiology, Duke University Medical Center, Durham, NC 27710.

Received 8/12/92. Accepted 10/20/92.




This article has been cited by other articles:


Home page
Cancer Res.Home page
S. Modak, K. Kramer, S. H. Gultekin, H. F. Guo, and N.-K. V. Cheung
Monoclonal Antibody 8H9 Targets a Novel Cell Surface Antigen Expressed by a Wide Spectrum of Human Solid Tumors
Cancer Res., May 1, 2001; 61(10): 4048 - 4054.
[Abstract] [Full Text]


Home page
J. Lipid Res.Home page
J. A. Ecsedy, H. C. Yohe, A. J. Bergeron, and T. N. Seyfried
Tumor-infiltrating macrophages influence the glycosphingolipid composition of murine brain tumors
J. Lipid Res., November 1, 1998; 39(11): 2218 - 2227.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1993 by the American Association for Cancer Research.